Evidence map›Paper›PMID 29870598›Full record

ArticleClinical pharmacology in drug development2019

Phase 1 Study of the Pharmacology of BTI320 Before High-Glycemic Meals.

David R Luke, Karen Ka Yan Lee, Carl W Rausch, Camille Cheng

Open access · hybridAbstract readClinical Trial, Phase I
In one paragraph

Article in Clinical pharmacology in drug development, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

David R LukeTarget Health Inc, New York, NY, USA.
Karen Ka Yan LeeBoston Therapeutics Inc, Lawrence, MA, USA.
Carl W RauschBoston Therapeutics Inc, Lawrence, MA, USA.
Camille ChengTarget Health Inc, New York, NY, USA.
Taiho Pharmaceutical (Japan) · JPTarget (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BTI320 is a proprietary fractionated mannan polysaccharide being studied for attenuation of postprandial glucose excursion. The apparent blood glucose-lowering effect of this compound is effective in lowering postprandial hyperinsulinemia, participating in the metabolic regulation of other lipid molecules; the consequence of this activity is yet to be validated with BTI320 with respect to the risk of cardiovascular disease. The primary objective of the study was to determine the postprandial glucose and insulin responses to 3 test meals containing rice alone or consumed with BTI320 (study A) or 3 test meals (Sprite

Indexed as

AdultAgedArea Under CurveBlood GlucoseBody Mass IndexCross-Over StudiesDietary CarbohydratesDietary SupplementsFemaleGlycemic IndexHealthy VolunteersHumansInsulinMaleMannansMiddle AgedBlood GlucoseDietary CarbohydratesInsulinMannansPAZ320TabletsBTI320glycemiainsulinemiaobesitypostprandial

Identifiers

PMID29870598
PMCPMC6585810
OpenAlexW2807277941

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.